TEVA-ZOLMITRIPTAN OD TABLET (ORALLY DISINTEGRATING)
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
06-04-2020
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
ZOLMITRIPTAN
Inapatikana kutoka:
TEVA CANADA LIMITED
ATC kanuni:
N02CC03
INN (Jina la Kimataifa):
ZOLMITRIPTAN
Kipimo:
2.5MG
Dawa fomu:
TABLET (ORALLY DISINTEGRATING)
Tungo:
ZOLMITRIPTAN 2.5MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
2/6
Dawa ya aina:
Prescription
Eneo la matibabu:
SELECTIVE SEROTONIN AGONISTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0134381001; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2011-06-07
Tabia za bidhaa
PRODUCT MONOGRAPH
PR
TEVA-ZOLMITRIPTAN
(zolmitriptan) tablets
2.5 mg
PR
TEVA-ZOLMITRIPTAN OD
(zolmitriptan) orally disintegrating tablets
2.5 mg
Teva Standard
Migraine Therapy
5-HT
1
Receptor Agonist
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
www.tevacanada.com
Submission Control No: 237687
Date of Revision:
April 6, 2020
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
12
DRUG INTERACTIONS
.........................................................................................................
18
DOSAGE AND ADMINISTRATION
.....................................................................................
19
OVERDOSAGE
.......................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 21
STORAGE AND STABILITY
.................................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 24
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
.................................................................................
25
CLINICAL TRIALS
...........................................
Soma hati kamili
